echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > How does obesity alter the immune system, and even immunotherapy response?

    How does obesity alter the immune system, and even immunotherapy response?

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    A team of researchers from the Gladstone Institute, the Salk Institute for Biological Studies and the University of California, San Francisco has discovered how obesity alters the immune system and how clinicians may be better able to treat allergies and asthma in obese people



    When mice with atopic dermatitis, a common allergic skin inflammation, were treated with drugs that target the immune system, their thickened, itchy skin usually healed quickly


    In the new study, researchers from the Gladstone Institutes, the Salk Institute for Biological Studies and the University of California, San Francisco (UCSF) collaborated


    Different types of T cell responses

    A recent study estimated that by 2030, roughly half of American adults will be classified as obese


    Sagar Bapat, MD (now a pathologist and faculty member at UCSF) on the study, Alex Ma, MD, senior author of the study and director of the Gladstone-UCSF Institute for Genomic Immunology Working in the lab of Alex Marson, he found that when mice became obese by eating a high-fat diet before inducing dermatitis, they developed more severe disease than lean animals


    "What we expected to see in the obese mice was just more severe inflammation," Bapat said.


    The body's helper T cells help protect against infection but can also become overactive in autoimmune diseases or allergies and can be divided into three categories: TH1, TH2 and TH17 cells


    In lean mice with atopic dermatitis, Bapat and his colleagues did find that TH2 cells were active


    In recent years, scientists have developed drugs to treat atopic dermatitis by inhibiting the response of TH2 cells


    "The treatment becomes a powerful counter-treatment," Bapat said


    The researchers suspect that dysfunction of a protein called PPAR-gamma may mediate the link between obesity and inflammation


    When the scientists treated obese mice with atopic dermatitis with a PPAR-gamma-activating drug called rosiglitazone, the animals' skin improved and the disease's molecular structure shifted from TH17 inflammation to TH2 inflammation


    "Basically, we immunized the mice to 'defat' the mice without changing their body weight," Bapat said


    back to patient

    The team also analyzed data from human allergic disease patients, including 59 patients with atopic dermatitis and hundreds of patients with asthma (another disease with a similar immune system response) who participated in a large Longitudinal study


    While more research in humans is needed, data suggest that, in humans and mice, obesity induces a shift in inflammation that leads to pathological changes in allergic disease and the effectiveness of immunotherapies targeting TH2-related inflammation
    .

    "We now want to know more about how the T-cell switch occurs," said senior author Ye Zheng, Ph.
    D.
    , associate professor in the Salk NOMIS Center for Immunobiology and Microbial Pathogenesis
    .
    "There are more details yet to be discovered, and they may be associated with a range of allergy- and asthma-related diseases
    .
    "

    However, the new study already points out that combining treatments targeting TH2 inflammation with PPAR-gamma drugs such as rosiglitazone could treat obese patients with atopic dermatitis
    .

    "In this case, our scientific findings can be applied very safely and rapidly to treatment in humans," Evans said.
    "
    Our preclinical findings suggest that these FDA-approved drugs may have unique combination treatments for some patients.
    benefit
    .
    "


    Obesity Alters Pathology and Treatment Response in Inflammatory Disease

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.